EndoCeutics

EndoCeutics is a private pharmaceutical company operating in the fields of women's health and the prevention and treatment of hormone-sensitive cancers. Following the approval by the U.S. FDA in November 2016 for the treatment of moderate to severe dysuria, a symptom of vulvovaginal atrophy (VVA) caused by menopause, Endoceutics focuses on developing non-estrogen therapies for sexual dysfunction and other symptoms of menopause, including hot flashes, osteoporosis, muscle loss, and type 2 diabetes. Hormonal therapies for breast cancer, uterine cancer, prostate cancer, male hypogonadism, and endometriosis are also under development. Endoceutics has five Phase III product candidates addressing significant market opportunities, as well as two Phase I/II candidates. Endoceutics holds global exclusive rights to patents, patent applications, technologies, and know-how for all its products.